` CTMX (CytomX Therapeutics Inc) vs S&P 500 Comparison - Alpha Spread

CTMX
vs
S&P 500

Over the past 12 months, CTMX has significantly outperformed S&P 500, delivering a return of +64% compared to the S&P 500's +13% growth.

Stocks Performance
CTMX vs S&P 500

Loading
CTMX
S&P 500
Add Stock
www.alphaspread.com

Performance Gap
CTMX vs S&P 500

Loading
CTMX
S&P 500
Difference
www.alphaspread.com

Performance By Year
CTMX vs S&P 500

Loading
CTMX
S&P 500
Add Stock

Competitors Performance
CytomX Therapeutics Inc vs Peers

S&P 500
CTMX
ABBV
AMGN
GILD
VRTX
Add Stock

CytomX Therapeutics Inc
Glance View

Market Cap
375.7m USD
Industry
Biotechnology

CytomX Therapeutics, Inc. engages in the development of antibody therapeutics for the treatment of cancer based on its Probody therapeutic technology platform. The company is headquartered in South San Francisco, California and currently employs 174 full-time employees. The company went IPO on 2015-10-08. The firm is developing a class of investigational conditionally activated therapeutics, based on its Probody technology platform, for the treatment of cancer. Its Probody technology platform is designed to enable conditional activation of antibody-based drugs in the tumor microenvironment while minimizing drug activity in healthy tissues and in circulation. The company has utilized its multi-modality Probody platform to build a pipeline of therapeutics that encompasses six product candidates, four of which are in multiple Phase II clinical studies in nine cancer indications. The company includes the conditionally activated antibody-drug conjugates (ADCs) praluzatamab ravtansine (CX-2009, targeting CD166) and CX-2029 (targeting CD71), and the Probody immune CPIs pacmilimab (CX-072, targeting PD-L1) and BMS-986249 (targeting CTLA-4).

CTMX Intrinsic Value
0.297 USD
Overvaluation 88%
Intrinsic Value
Price
Back to Top